A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) …
JW Neal, HA Wakelee, JL Feliciano, SB Goldberg… - 2014 - ascopubs.org
8088 Background: Erlotinib (E) is widely used in the treatment of advanced EGFR mutant
NSCLC, with a historical progression free survival of about 9 months. Preclinical data …
NSCLC, with a historical progression free survival of about 9 months. Preclinical data …
Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
A phase II trial of erlotinib monotherapy in pretreated patients (pts) with non-small cell lung cancer (NSCLC) who do not possess active EGFR mutations
H Yoshioka, H Hayashi, K Kiura, N Takigawa… - Journal of Clinical …, 2009 - ascopubs.org
8067 Background: Efficacy of gefitinib therapy strongly depends on the presence of active
EGFR mutations in Asian NSCLC pts, with objective response rates (ORR) of 71.2% and …
EGFR mutations in Asian NSCLC pts, with objective response rates (ORR) of 71.2% and …
A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating …
Y Nakahara, Y Hosomi, K Yamada, H Okamoto, T Kato… - 2014 - ascopubs.org
8080 Background: Erlotinib and gefitinib have been shown to have similar activity for EGFR
mutation-positive (EGFRm+) NSCLC. Since the steady-state plasma trough concentration of …
mutation-positive (EGFRm+) NSCLC. Since the steady-state plasma trough concentration of …
A phase II study of erlotinib monotherpay in patients with previously treated advanced non-small cell lung cancer (NSCLC) without EGFR gene mutation who have …
Y Ishii, M Maemondo, K Okudera, K Takamura… - 2012 - ascopubs.org
7561 Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
have demonstrated good response in NSCLC harboring EGFR gene mutation. However …
have demonstrated good response in NSCLC harboring EGFR gene mutation. However …
[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients
Background No consensus has been reached regarding the treatment order and timing of
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and cytotoxic …
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and cytotoxic …
[PDF][PDF] First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations
JW Neal, LV Sequist - Clin Adv Hematol Oncol, 2010 - hematologyandoncology.net
While the small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
erlotinib and gefitinib have modest clinical benefit in unselected patients with non–small cell …
erlotinib and gefitinib have modest clinical benefit in unselected patients with non–small cell …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations
N Koyama, Y Uchida - Anticancer Research, 2013 - ar.iiarjournals.org
Background: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …